Downregulation of miR‑141 deactivates hepatic stellate cells by targeting the PTEN/AKT/mTOR pathway

Liang,Haijun; Wang,Xinwei; Si,Changyun; Duan,Yuxiu; Chen,Baoxin; Liang,Haixia; Yang,Daokun

doi:10.3892/ijmm.2020.4578

Downregulation of miR‑141 deactivates hepatic stellate cells by targeting the PTEN/AKT/mTOR pathway

Authors:
- Haijun Liang
- Xinwei Wang
- Changyun Si
- Yuxiu Duan
- Baoxin Chen
- Haixia Liang
- Daokun Yang
View Affiliations

Affiliations: Department of Infectious Disease, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China, Department of Neurology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China
Published online on: April 15, 2020 https://doi.org/10.3892/ijmm.2020.4578
Pages: 406-414

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The activation of hepatic stellate cells (HSCs) caused by stimulating factors or fibrogenic cytokines is the critical stage of liver fibrosis. Recent studies have demonstrated the influence of microRNAs (miRNAs or miRs) on HSC activation and transformation; however, the function and underlying mechanisms of miRNAs in HSC activation have not yet been completely clarified. In the present study, transforming growth factor β1 (TGF‑β1) was used to treat human HSC lines (HSC‑T6 and LX2 cells) to simulate the activation of HSCs in vivo and whether the expression of miRNAs in HSCs was affected by TGF‑β1 treatment was examined using a miRNA microarray. It was observed that miR‑141 was one of the most upregulated miRNAs during HSC activation. Functional analyses revealed that miR‑141 knockdown suppressed the viability of HSCs and inhibited the expression levels of pro‑fibrotic markers. In addition, phosphatase and tensin homolog (PTEN), a well‑known suppressor of the AKT/mammalian target of rapamycin (mTOR) pathway, was found to be directly targeted by miR‑141 in HSCs. More importantly, the knockdown of PTEN markedly reversed the suppressive effects of miR‑141 inhibition on the viability of and the expression levels of pro‑fibrotic markers during HSC activation. Finally, it was observed that the downregulation of miR‑141 blocked the TGF‑β1‑induced activation of the AKT/mTOR pathway in HSCs. On the whole, the findings of the present study indicate that miR‑141 inhibition suppresses HSC activation via the AKT/mTOR pathway by targeting PTEN, highlighting that miR‑141 may serve as a novel therapeutic target for liver fibrosis.

View Figures

View References

1	Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology. 134:1655–1669. 2008. View Article : Google Scholar : PubMed/NCBI
2	Bao S, Zheng J and Shi G: The role of T helper 17 cells in the pathogenesis of hepatitis B virus-related liver cirrhosis (Review). Mol Med Rep. 16:3713–3719. 2017. View Article : Google Scholar : PubMed/NCBI
3	Roeb E: Matrix metalloproteinases and liver fibrosis (translational aspects). Matrix Biol. 68-69:463–473. 2018. View Article : Google Scholar : PubMed/NCBI
4	Yu F, Fan X, Chen B, Dong P and Zheng J: Activation of hepatic stellate cells is inhibited by microRNA-378a-3p via Wnt10a. Cell Physiol Biochem. 39:2409–2420. 2016. View Article : Google Scholar : PubMed/NCBI
5	Li T and Cho WC: MicroRNAs: Mechanisms, functions and progress. Genomics Proteomics Bioinformatics. 10:237–238. 2012. View Article : Google Scholar : PubMed/NCBI
6	Rottiers V and Naar AM: MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 13:239–250. 2012. View Article : Google Scholar : PubMed/NCBI
7	Sud N, Taher J and Su Q: MicroRNAs and noncoding RNAs in hepatic lipid and lipoprotein metabolism: Potential therapeutic targets of metabolic disorders. Drug Dev Res. 76:318–327. 2015. View Article : Google Scholar : PubMed/NCBI
8	Wei S, Wang Q, Zhou H, Qiu J, Li C, Shi C, Zhou S, Liu R and Lu L: MiR-455-3p alleviates hepatic stellate cell activation and liver fibrosis by suppressing HSF1 expression. Mol Ther Nucleic Acids. 16:758–769. 2019. View Article : Google Scholar : PubMed/NCBI
9	Zou Y, Li S, Li Z, Song D, Zhang S and Yao Q: MiR-146a attenuates liver fibrosis by inhibiting transforming growth factor-β1 mediated epithelial-mesenchymal transition in hepatocytes. Cell Signal. 58:1–8. 2019. View Article : Google Scholar : PubMed/NCBI
10	He Y, Huang C, Zhang SP, Sun X, Long XR and Li J: The potential of microRNAs in liver fibrosis. Cell Signal. 24:2268–2272. 2012. View Article : Google Scholar : PubMed/NCBI
11	Noetel A, Kwiecinski M, Elfimova N, Huang J and Odenthal M: MicroRNA are central players in anti- and profibrotic gene regulation during liver fibrosis. Front Physiol. 3:492012. View Article : Google Scholar : PubMed/NCBI
12	Sun J, Zhang H, Li L, Yu L and Fu L: MicroRNA-9 limits hepatic fibrosis by suppressing the activation and proliferation of hepatic stellate cells by directly targeting MRP1/ABCC1. Oncol Rep. 37:1698–1706. 2017. View Article : Google Scholar : PubMed/NCBI
13	Ju B, Nie Y, Yang X, Wang X, Li F, Wang M, Wang C and Zhang H: Mir-193a/b-3p relieves hepatic fibrosis and restrains proliferation and activation of hepatic stellate cells. J Cell Mol Med. 23:3824–3832. 2019. View Article : Google Scholar : PubMed/NCBI
14	Peng J, He X, Zhang L and Liu P: MicroRNA26a protects vascular smooth muscle cells against H2O2induced injury through activation of the PTEN/AKT/mTOR pathway. Int J Mol Med. 42:1367–1378. 2018.PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
16	Yao Y, Sun F and Lei M: MiR-25 inhibits sepsis-induced cardio-myocyte apoptosis by targetting PTEN. Biosci Rep. 13:382018.
17	Mimche PN, Lee CM, Mimche SM, Thapa M, Grakoui A, Henkemeyer M and Lamb TJ: EphB2 receptor tyrosine kinase promotes hepatic fibrogenesis in mice via activation of hepatic stellate cells. Sci Rep. 8:25322018. View Article : Google Scholar : PubMed/NCBI
18	Ma L, Yang X, Wei R, Ye T, Zhou JK, Wen M, Men R, Li P, Dong B, Liu L, et al: MicroRNA-214 promotes hepatic stellate cell activation and liver fibrosis by suppressing sufu expression. Cell Death Dis. 9:7182018. View Article : Google Scholar : PubMed/NCBI
19	Wang P, Lei S, Wang X, Xu W, Hu P, Chen F, Zhang X, Yin C and Xie W: MicroRNA-134 deactivates hepatic stellate cells by targeting TGF-β activated kinase 1-binding protein 1. Biochem Cell Biol. 97:505–512. 2019. View Article : Google Scholar : PubMed/NCBI
20	Mormone E, George J and Nieto N: Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact. 193:225–231. 2011. View Article : Google Scholar : PubMed/NCBI
21	Liu Y, Zhao R, Wang H, Luo Y, Wang X, Niu W, Zhou Y, Wen Q, Fan S, Li X, et al: MiR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma. Cell Death Dis. 7:e21562016. View Article : Google Scholar : PubMed/NCBI
22	Huang TJ, Ren JJ, Zhang QQ, Kong YY, Zhang HY, Guo XH, Fan HQ and Liu LX: IGFBPrP1 accelerates autophagy and activation of hepatic stellate cells via mutual regulation between H19 and PI3K/AKT/mTOR pathway. Biomed Pharmacother. 116:1090342019. View Article : Google Scholar : PubMed/NCBI
23	Guerrero-Zotano A, Mayer IA and Arteaga CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016. View Article : Google Scholar : PubMed/NCBI
24	Bai T, Lian LH, Wu YL, Wan Y and Nan JX: Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells. Int Immunopharmacol. 15:275–281. 2013. View Article : Google Scholar : PubMed/NCBI
25	Feng MH, Li JW, Sun HT, He SQ and Pang J: Sulforaphane inhibits the activation of hepatic stellate cell by miRNA-423-5p targeting suppressor of fused. Hum Cell. 32:403–410. 2019. View Article : Google Scholar : PubMed/NCBI
26	Huang YH, Kuo HC, Yang YL and Wang FS: MicroRNA-29a is a key regulon that regulates BRD4 and mitigates liver fibrosis in mice by inhibiting hepatic stellate cell activation. Int J Med Sci. 16:212–220. 2019. View Article : Google Scholar : PubMed/NCBI
27	Tao L, Xue D, Shen D, Ma W, Zhang J, Wang X, Zhang W, Wu L, Pan K, Yang Y, et al: MicroRNA-942 mediates hepatic stellate cell activation by regulating BAMBI expression in human liver fibrosis. Arch Toxicol. 92:2935–2946. 2018. View Article : Google Scholar : PubMed/NCBI
28	Li Z, Ji L, Su S, Zhu X, Cheng F, Jia X, Zhou Q and Zhou Y: Leptin up-regulates microRNA-27a/b-3p level in hepatic stellate cells. Exp Cell Res. 366:63–70. 2018. View Article : Google Scholar : PubMed/NCBI
29	Wang YZ, Zhang W, Wang YH, Fu XL and Xue CQ: Repression of liver cirrhosis achieved by inhibitory effect of miR-454 on hepatic stellate cells activation and proliferation via wnt10a. J Biochem. 165:361–367. 2019. View Article : Google Scholar
30	Sekiya Y, Ogawa T, Yoshizato K, Ikeda K and Kawada N: Suppression of hepatic stellate cell activation by microRNA-29b. Biochem Biophys Res Commun. 412:74–79. 2011. View Article : Google Scholar : PubMed/NCBI
31	Wang J, Chu ES, Chen HY, Man K, Go MY, Huang XR, Lan HY, Sung JJ and Yu J: MicroRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget. 6:7325–7338. 2015. View Article : Google Scholar :
32	Ji J, Zhang J, Huang G, Qian J, Wang X and Mei S: Over-Expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett. 583:759–766. 2009. View Article : Google Scholar : PubMed/NCBI
33	Zhou B and Yu JW: A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-β1. Biochem Biophys Res Commun. 487:769–775. 2017. View Article : Google Scholar : PubMed/NCBI
34	Li XY, Wang SS, Han Z, Han F, Chang YP, Yang Y, Xue M, Sun B and Chen LM: Triptolide restores autophagy to alleviate diabetic renal fibrosis through the miR-141-3p/PTEN/Akt/mTOR Pathway. Mol Ther Nucleic Acids. 9:48–56. 2017. View Article : Google Scholar : PubMed/NCBI
35	Tan Y, Pan T, Ye Y, Ge G, Chen L, Wen D and Zou S: Serum microRNAs as potential biomarkers of primary biliary cirrhosis. PLoS One. 9:e1114242014. View Article : Google Scholar : PubMed/NCBI
36	Hao LS, Zhang XL, An JY, Karlin J, Tian XP, Dun ZN, Xie SR and Chen S: PTEN expression is down-regulated in liver tissues of rats with hepatic fibrosis induced by biliary stenosis. APMIS. 117:681–691. 2009. View Article : Google Scholar : PubMed/NCBI
37	Zheng L, Chen X, Guo J, Sun H, Liu L, Shih DQ and Zhang X: Differential expression of PTEN in hepatic tissue and hepatic stellate cells during rat liver fibrosis and its reversal. Int J Mol Med. 30:1424–1430. 2012. View Article : Google Scholar : PubMed/NCBI
38	Tao H, Zhang JG, Qin RH, Dai C, Shi P, Yang JJ, Deng ZY and Shi KH: LncRNA GAS5 controls cardiac fibroblast activation and fibrosis by targeting miR-21 via PTEN/MMP-2 signaling pathway. Toxicology. 386:11–18. 2017. View Article : Google Scholar : PubMed/NCBI
39	McClelland AD, Herman-Edelstein M, Komers R, Jha JC, Winbanks CE, Hagiwara S, Gregorevic P, Kantharidis P and Cooper ME: MiR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin Sci (Lond). 129:1237–1249. 2015. View Article : Google Scholar
40	Parapuram SK, Shi-wen X, Elliott C, Welch ID, Jones H, Baron M, Denton CP, Abraham DJ and Leask A: Loss of PTEN expression by dermal fibroblasts causes skin fibrosis. J Invest Dermatol. 131:1996–2003. 2011. View Article : Google Scholar : PubMed/NCBI
41	He L, Gubbins J, Peng Z, Medina V, Fei F, Asahina K, Wang J, Kahn M, Rountree CB and Stiles BL: Activation of hepatic stellate cell in pten null liver injury model. Fibrogenesis Tissue Repair. 9:82016. View Article : Google Scholar : PubMed/NCBI
42	Niu X, Fu N, Du J, Wang R, Wang Y, Zhao S, Du H, Wan B, Zhang Y, Sun D and Nan Y: MiR-1273g-3p modulates activation and apoptosis of hepatic stellate cells by directly targeting PTEN in HCV-related liver fibrosis. FEBS Lett. 590:2709–2724. 2016. View Article : Google Scholar : PubMed/NCBI
43	Zheng J, Wu C, Xu Z, Xia P, Dong P, Chen B and Yu F: Hepatic stellate cell is activated by microRNA-181b via PTEN/Akt pathway. Mol Cell Biochem. 398:1–9. 2015. View Article : Google Scholar
44	Voloshenyuk TG, Landesman ES, Khoutorova E, Hart AD and Gardner JD: Induction of cardiac fibroblast lysyl oxidase by TGF-β1 requires PI3K/Akt, Smad3, and MAPK signaling. Cytokine. 55:90–97. 2011. View Article : Google Scholar : PubMed/NCBI
45	Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 275:2247–2250. 2000. View Article : Google Scholar : PubMed/NCBI
46	Son G, Hines IN, Lindquist J, Schrum LW and Rippe RA: Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis. Hepatology. 50:1512–1523. 2009. View Article : Google Scholar : PubMed/NCBI
47	Reif S, Lang A, Lindquist JN, Yata Y, Gabele E, Scanga A, Brenner DA and Rippe RA: The role of focal adhesion kinase-phosphatidylinositol 3-kinase-akt signaling in hepatic stellate cell proliferation and type I collagen expression. J Biol Chem. 278:8083–8090. 2003. View Article : Google Scholar
48	Wu SM, Li TH, Yun H, Ai HW and Zhang KH: MiR-140-3p knockdown suppresses cell proliferation and fibrogenesis in hepatic stellate cells via PTEN-Mediated AKT/mTOR signaling. Yonsei Med J. 60:561–569. 2019. View Article : Google Scholar : PubMed/NCBI